The role of cytotoxic chemotherapy in the management of progressive glioblastoma: A systematic review and evidence-based clinical practice guideline

Journal of Neuro-Oncology

Volumn 118, Issue 3, 2014, Pages 501-555

  Olson, Jeffrey J ^a   Nayak, Lakshmi ^b   Ormond, D Ryan ^a   Wen, Patrick Y ^b   Kalkanis, Steven N ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Adult; Chemotherapy; Cytotoxic; Glioblastoma; Mortality; Progressive; Recurrent; Relapsing; Survival; Temozolomide

Indexed keywords

CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; ETOPOSIDE; FOTEMUSTINE; GLUFOSFAMIDE; IFOSFAMIDE; IRINOTECAN; LAROMUSTINE; LOMUSTINE; NITROSOUREA; NITROSOUREA DERIVATIVE; PLATINUM COMPLEX; POLYMER; PROCARBAZINE; SAGOPILONE; TEMOZOLOMIDE; TOPOTECAN; TREOSULFAN; VINCRISTINE;

ADJUVANT THERAPY; BIODEGRADABILITY; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CASE STUDY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG TOLERABILITY; GLIOBLASTOMA; HEALTH STATUS; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MEDICAL DECISION MAKING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC DISEASE; THROMBOCYTOPENIA;

ABSORBABLE IMPLANTS; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; GLIOBLASTOMA; HUMANS;

EID: 84903817839     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1338-5     Document Type: Review

References (112)

1. CBTRUS (2010) CBTRUS Statistical Report: Primary brain and central nervous system tumors in the United States in 2004-2006. Published by the Central Brain Tumor Registry of the United States, Hinsdale
2. Darefsky AS, King JT Jr, Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 118(8):2163-2172
3. Koshy M, Villano JL, Dolecek TA et al (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1):207-212
4. Olson JJ, Fadul CE, Brat DJ, Mukundan S, Ryken TC (2009) Management of newly diagnosed glioblastoma: guidelines development, value and application. J Neurooncol 93(1):1-23
5. Easaw JC, Mason WP, Perry J, et al (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol (Toronto, Ont.) 18(3):e126-e136
6. Olson JJ, Ryken T (2008) Guidelines for the treatment of newly diagnosed glioblastoma: introduction. J Neurooncol 89(3):255-258
7. Fabrini MG, Silvano G, Lolli I et al (2009) A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 92(1):79-86
8. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 352(10):987-996 (Pubitemid 40349501)
9. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Brit J Cancer 83(5):588-593 (Pubitemid 30636298)
10. Brandes AA, Ermani M, Basso U et al (2001) Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol 12(2):255-257 (Pubitemid 32223878)
11. Brandes AA, Turazzi S, Basso U et al (2002) A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology. 58(12):1759-1764 (Pubitemid 34663574)
12. Aoki T, Mizutani T, Ishikawa M, Sugiyama K, Hashimoto N (2003) A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. Int J Clin Oncol 8(5):301-304 (Pubitemid 37370255)
13. Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12(2):259-266 (Pubitemid 32223879)
14. Chang SM, Theodosopoulos P, Lamborn K et al (2004) Temozolomide in the treatment of recurrent malignant glioma. Cancer 100(3):605-611 (Pubitemid 38124780)
15. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE (2002) A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol 4(1):39-43 (Pubitemid 34269465)
16. Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M (2011) Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neurooncol 103(3):585-593
17. Kong DS, Lee JI, Kim WS, et al (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide- refractory glioblastoma. Oncol Rep 16:1117-1121
18. Kong DS, Lee JI, Kim JH et al (2010) Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12(3):289-296
19. Perry JR, Rizek P, Cashman R, Morrison M, Morrison T (2008) Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer 113(8):2152-2157
20. Perry JR, Belanger K, Mason WP et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: rescue study. J Clin Oncol 28(12):2051-2057
21. Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 62(11):2113-2115 (Pubitemid 38738235)
22. Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25(22):3357-3361 (Pubitemid 47325623)
23. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572-2578 (Pubitemid 29368260)
24. Brandes AA, Tosoni A, Cavallo G et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Brit J Cancer 95(9):1155-1160 (Pubitemid 44658477)
25. Balmaceda C, Peereboom D, Pannullo S et al (2008) Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 112(5):1139-1146 (Pubitemid 351304600)
26. Trippoli S, Pelagotti F, Messori A, Vacca F, Vaiani M, Maltoni S (2003) Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. Drugs R&D. 4(5):285-291 (Pubitemid 37184389)
27. Everaert E, Neyns B, Joosens E, Strauven T, Branle F, Menten J (2004) Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. J Neurooncol 70(1):37-48 (Pubitemid 39193996)
28. Caroli M, Locatelli M, Campanella R et al (2007) Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? J Neurooncol 84(1):71-77 (Pubitemid 47103446)
29. Taal W, Segers-van Rijn JM, Kros JM, et al (2012) Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. J Neurooncol 108(1):195-200
30. Hassler M, Micksche M, Stockhammer G et al (2006) Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study. Wiener klinische Wochenschrift. 118(7-8):230-238 (Pubitemid 44011724)
31. Wick A, Pascher C, Wick W et al (2009) Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol. 256(5):734-741
32. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104(11):2473-2476 (Pubitemid 41691570)
33. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459-466
34. Stupp R, Tosoni A, Bromberg JE, et al (2011) Sagopilone (ZKEPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol 22(9):2144-2149
35. Brandes AA, Tosoni A, Amista P et al (2004) How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 63(7):1281-1284 (Pubitemid 39350031)
36. Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G (2010) BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC cancer 10:30
37. Newton HB (2005) Intra-arterial chemotherapy of primary brain tumors. Curr Treat Options Oncol 6(6):519-530
38. Hiesiger EM, Green SB, Shapiro WR et al (1995) Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A. J Neurooncol 25(2):143-154
39. Figueiredo EG, Faria JW, Teixeira MJ (2010) Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea]. Arquivos de neuro-psiquiatria. 68(5):778-782
40. Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet. 345(8956):1008-1012
41. Perry J, Chambers A, Spithoff K, Laperriere N (2007) Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol (Toronto, Ont.). 14(5):189-194
42. Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D (1999) Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery.45(1):17-22; discussion 22-13
43. Gururangan S, Cokgor L, Rich JN et al (2001) Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol 3(4):246-250 (Pubitemid 33674145)
44. Quinn JA, Jiang SX, Carter J et al (2009) Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res. 15(3):1064-1068
45. Frenay M, Giroux B, Khoury S, Derlon JM, Namer M (1991) Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer (Oxford, England: 1990). 27(7):852-856
46. Scoccianti S, Detti B, Sardaro A et al (2008) Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anti Cancer Drugs 19(6):613-620
47. Brandes AA, Tosoni A, Franceschi E et al (2009) Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 64(4):769-775
48. Fabi A, Metro G, Russillo M et al (2009) Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. BMC Cancer 9:101
49. Fabi A, Metro G, Vidiri A et al (2010) Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. J Neurooncol 100(2):209-215
50. Addeo R, Caraglia M, De Santi MS et al (2011) A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol 102(3):417-424
51. Poisson M, Chiras J, Fauchon F, Debussche C, Delattre JY (1990) Treatment of malignant recurrent glioma by intra-arterial, infra-ophthalmic infusion of HECNU 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl) urea. A phase II study. J Neurooncol 8(3):255-262 (Pubitemid 20213299)
52. Gregor A, Rampling R, Aapro M, et al (1992) Phase II study of tauromustine in malignant glioma. Eur J Cancer (Oxford, England: 1990). 28A(12):1959-1962
53. Durando X, Thivat E, Roche H et al (2006) Cystemustine in recurrent high grade glioma. J Neurooncol 79(1):33-37 (Pubitemid 44057413)
54. Chamberlain MC, Johnston SK (2011) Salvage therapy with single agent bendamustine for recurrent glioblastoma. J Neurooncol 105(3):523-530
55. Friedman HS, Petros WP, Friedman AH et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17(5):1516-1525 (Pubitemid 29220860)
56. Prados MD, Lamborn K, Yung WKA et al (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol 8:189-193 (Pubitemid 46542664)
57. Bruce JN, Fine RL, Canoll P, et al (2011) Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery. 69(6):1272-1279; discussion 1279-1280
58. Warnick RE, Prados MD, Mack EE et al (1994) A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 19(1):69-74 (Pubitemid 24258542)
59. Prados MD, Warnick RE, Mack EE et al (1996) Intravenous carboplatin for recurrent gliomas. A dose-escalating phase II trial. Am J Clin Oncol 19(6):609-612 (Pubitemid 26384713)
60. Murray LJ, Bridgewater CH, Levy D (2011) Carboplatin chemotherapy in patients with recurrent high-grade glioma. Clin Oncol (Royal College of Radiologists Great Britain). 23(1):55-61
61. Cloughesy TF, Gobin YP, Black KL et al (1997) Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J Neurooncol 35(2):121-131 (Pubitemid 27361680)
62. Fulton D, Urtasun R, Forsyth P (1996) Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 27(2):149-155 (Pubitemid 26052650)
63. Clarke K, Basser RL, Underhill C et al (1999) KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma. J Clin Oncol 17(8):2579-2584 (Pubitemid 29368261)
64. Twelves C, Campone M, Coudert B et al (2002) Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol 13(5):777-780 (Pubitemid 34567386)
65. Paulsen F, Hoffmann W, Becker G et al (1999) Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. J Cancer Res Clin Oncol 125(7):411-418 (Pubitemid 29287500)
66. van den Bent MJ, Grisold W, Frappaz D et al (2003) European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-min infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 14(12):1732-1734 (Pubitemid 38029044)
67. Chamberlain MC, Tsao-Wei DD (2004) Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 100(6):1213-1220 (Pubitemid 38325950)
68. Schmidt F, Wick W, Herrlinger U, Dichgans J, Weller M (2000) Treosulfan chemotherapy for recurrent malignant glioma. J Neurooncol 49(3):231-234 (Pubitemid 32106785)
69. Sanson M, Napolitano M, Yaya R et al (2000) Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 50(3):245-249 (Pubitemid 32192876)
70. Fabel K, Dietrich J, Hau P et al (2001) Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92(7):1936-1942 (Pubitemid 32952514)
71. Glas M, Koch H, Hirschmann B et al (2007) Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series. Oncology 72(5-6):302-307 (Pubitemid 351238141)
72. Badruddoja MA, Penne K, Desjardins A et al (2007) Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol 9(1):70-74 (Pubitemid 46543491)
73. Oehler C, Frei K, Rushing EJ et al (2012) Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. Oncology 83(1):1-9
74. Kappelle AC, Postma TJ, Taphoorn MJ et al (2001) PCV chemotherapy for recurrent glioblastoma multiforme. Neurology. 56(1):118-120 (Pubitemid 32059666)
75. Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M (2006) PCV chemotherapy for recurrent glioblastoma. Neurology. 66(4):587-589 (Pubitemid 43739895)
76. Watne K, Hannisdal E, Nome O, Hager B, Hirschberg H (1992) Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. Neurosurgery. 30(2):223-227
77. Ameri A, Poisson M, Chen QM, Delattre JY (1993) Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. J Neurooncol 17(1):43-46 (Pubitemid 24006748)
78. Gruber ML, Buster WP (2004) Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol 27(1):33-38 (Pubitemid 38176289)
79. Reardon DA, Quinn JA, Rich JN et al (2005) Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104(7):1478-1486 (Pubitemid 41356163)
80. Silvani A, Eoli M, Salmaggi A et al (2004) Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol 66(1-2):203-208 (Pubitemid 38258376)
81. Zustovich F, Lombardi G, Della Puppa A, Rotilio A, Scienza R, Pastorelli D (2009) A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomiderefractory high-grade malignant glioma. Anticancer Res. 29(10):4275-4279
82. Chua SL, Rosenthal MA, Wong SS et al (2004) Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol 6(1):38-43 (Pubitemid 38139638)
83. Prados MD, Seiferheld W, Sandler HM et al (2004) Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys. 58(4):1147-1152 (Pubitemid 38314798)
84. Boiardi A, Eoli M, Salmaggi A et al (2005) Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma. J Neurooncol 75(2):215-220 (Pubitemid 41819728)
85. Santoni M, Paccapelo A, Burattini L, Onofri A, Cascinu S (2012) Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma. Anticancer Res 32(3):1099-1101
86. Hildebrand J, De Witte O, Sahmoud T (1998) Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine - a phase-II study. J Neurooncol 37(2):155-160 (Pubitemid 28073588)
87. Brandes AA, Tosoni A, Basso U et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22(23):4779-4786
88. Kuhnhenn J, Kowalski T, Steenken S, Ostermann K, Schlegel U (2012) Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis. J Neurooncol 109(2):433-438
89. Rosenthal MA, Gruber ML, Glass J et al (2000) Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme. J Neurooncol 47(1):59-63 (Pubitemid 30458407)
90. Fazeny-Dorner B, Veitl M, Wenzel C et al (2003) Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Anticancer Drugs 14(6):437-442 (Pubitemid 36951794)
91. Silvani A, Lamperti E, Gaviani P et al (2008) Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol 87(2):143-151
92. Gwak HS, Youn SM, Kwon AH, Lee SH, Kim JH, Rhee CH (2005) ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study. J Neurooncol 75(2):173-180 (Pubitemid 41819721)
93. 26) in recurrent glioblastoma. Oncology 76(3):184-189
94. Sanson M, Ameri A, Monjour A, et al (1996) Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur J Cancer (Oxford, England: 1990). 32A(13):2229-2235
95. Ameri A, Poisson M, Chauveinc L, Chen QM, Delattre JY (1997) Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study. J Neurooncol 32(2):155-160 (Pubitemid 27077984)
96. Ashby LS, Shapiro WR (2001) Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study. J Neurooncol 51(1):67-86 (Pubitemid 32321904)
97. Franceschi E, Cavallo G, Scopece L et al (2004) Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Brit J Cancer 91(6):1038-1044 (Pubitemid 39336240)
98. Robins HI, Chang SM, Prados MD et al (2002) A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol 4(2):109-114 (Pubitemid 34285065)
99. Poisson M, Pereon Y, Chiras J, Delattre JY (1991) Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neurooncol 10(2):139-144
100. Yung WK, Mechtler L, Gleason MJ (1991) Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9(5):860-864
101. Aoki T, Mizutani T, Nojima K et al (2010) Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. J Neurosurg. 112(1):50-56
102. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 13(4):1253-1259 (Pubitemid 46424067)
103. Schafer N, Tichy J, Thanendrarajan S et al (2011) Ifosfamide, carboplatin and etoposide in recurrent malignant glioma. Oncology 80(5-6):330-332
104. Boiardi A, Silvani A, Milanesi I, Broggi G, Fariselli L (1992) Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients. J Neurooncol 12(2):153-158
105. Boiardi A, Silvani A, Croci D, Perego E, Solero CL (1992) Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM). Italian J Neurol Sci 13(7):583-588
106. Herrlinger U, Rieger J, Steinbach JP, Nagele T, Dichgans J, Weller M (2005) UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J Neurooncol 71(3):295-299 (Pubitemid 40372960)
107. Wen PY, Schiff D, Cloughesy TF et al (2011) It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol 29(24):3211-3213
108. Demeule M, Regina A, Che C et al (2008) Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exper Ther 324(3):1064-1072 (Pubitemid 351397849)
109. Allard E, Passirani C, Benoit JP (2009) Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 30(12):2302-2318
110. Kemper EM, Boogerd W, Thuis I, Beijnen JH, van Tellingen O (2004) Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 30(5):415-423 (Pubitemid 38968122)
111. van den Bent MJ, Pronk L, Sillevis Smitt PAE et al (1999) Phase II study of weekly dose intensified cisplatin chemotherapy with oral etoposide in recurrent glioma. J Neurooncol 44:59-64 (Pubitemid 29515651)
112. Stein ME, Kuten A, Drumea K et al (1999) Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure: a clinical study conducted at the Northern Israel Oncology Center. J Surg Oncol 71(3):167-170 (Pubitemid 29340780)